GlassScriptPhysician profile
Joni Hamblin
NPI 1376007237
$2,572.88
in general payments reported to CMS, 2019-2025
18 companies · $566 in 2025
The $566 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $243 · 2023: $351 · 2024: $1,017 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $543.11 | 2021-2025 | Sublocade, Perseris |
| Alkermes, INC. | $351.63 | 2021-2025 | Lybalvi, Vivitrol |
| Abbvie INC. | $276.50 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $268.28 | 2021-2024 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $232.60 | 2024 | Qelbree |
| Neurocrine Biosciences, INC. | $213.81 | 2022-2025 | Ingrezza |
| Braeburn INC. | $122.28 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $115.36 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $71.66 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $71.16 | 2021-2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $69.80 | 2022-2025 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.30 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $50.63 | 2022 | |
| Ironshore Pharmaceuticals INC. | $47.96 | 2022-2024 | |
| Biogen, INC. | $20.80 | 2024 | Zurzuvae |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.58 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $17.88 | 2023 | Trintellix |
| Axsome Therapeutics, INC. | $14.54 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joni Hamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.